SWOT Analysis for Mereo Biopharma Group Plc - ADR

Consistent Highest Return Stocks over Five Years - Nifty500
Significant (over 30%) distance from 52 week high
Rising Net Cash Flow and Cash from Operating activity
Annual Profit Growth higher than Sector Profit Growth
Company with Low Debt
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Stock with Low PE (PE < = 10)
Volume Shockers

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Stock with Low PE (PE < = 10)

Volume Shockers

Stocks with Quarter Change % less than Industry
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Lowest Momentum Scores (Technical Scores)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Weak Momentum: Price below Short, Medium and Long Term Averages
Declining profits every quarter for the past 2 quarters
RSI indicating price weakness
Near 52 Week Low
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter

Stocks with Quarter Change % less than Industry

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Lowest Momentum Scores (Technical Scores)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Highest fall from 52 Week High

Top Losers

Low Piotroski Score : Companies with weak financials

Book Value Per Share deteriorating for last 2 years

Weak Momentum: Price below Short, Medium and Long Term Averages

Declining profits every quarter for the past 2 quarters

RSI indicating price weakness

Near 52 Week Low

Top Losers

Stocks Underperforming their Industry Price Change in the Quarter

Forecaster Consensus Estimates: Stocks with Strong Buy Calls from Analysts
Institutions increasing their shareholding
Mutual Funds Increased Shareholding over the Past Two Months
MFs increased their shareholding last quarter

Forecaster Consensus Estimates: Stocks with Strong Buy Calls from Analysts

Institutions increasing their shareholding

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Mutual Funds Decreased Shareholding in Past Month

Mutual Funds Decreased Shareholding in Past Month

Mereo Biopharma Group Plc - ADR SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Mereo Biopharma Group Plc - ADR has 9 Strengths, 16 Weaknesses, 4 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Consistent Highest Return Stocks over Five Years - Nifty500

Significant (over 30%) distance from 52 week high

Rising Net Cash Flow and Cash from Operating activity

Annual Profit Growth higher than Sector Profit Growth

Company with Low Debt

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Stock with Low PE (PE < = 10)

Volume Shockers

Stocks with Quarter Change % less than Industry

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Lowest Momentum Scores (Technical Scores)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Highest fall from 52 Week High

Top Losers

Low Piotroski Score : Companies with weak financials

Book Value Per Share deteriorating for last 2 years

Weak Momentum: Price below Short, Medium and Long Term Averages

Declining profits every quarter for the past 2 quarters

RSI indicating price weakness

Near 52 Week Low

Top Losers

Stocks Underperforming their Industry Price Change in the Quarter

Forecaster Consensus Estimates: Stocks with Strong Buy Calls from Analysts

Institutions increasing their shareholding

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Mutual Funds Decreased Shareholding in Past Month